Categories: HealthDay

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

TUESDAY, June 5, 2018 (HealthDay News) — The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

A biosimilar drug, generally derived from a living organism, is approved based on clinical evidence that it is “highly similar” to a product that’s already approved by the FDA, and that there are “no clinically meaningful differences” in safety, purity and potency, the agency said.

The most common side effects of Fulphila are pain in the bones, arms and legs. Less common but more serious adverse reactions include the possibility of spleen rupture, severe respiratory problems and allergic reactions, glomerulonephritis, leukocytosis, tumor growth, and “fatal sickle cell crises,” the FDA said.

“We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from [price] competition to existing biologics once lawful intellectual property has lapsed on these products,” FDA Commissioner Scott Gottlieb, M.D., said in a statement.

Fulphila is produced by Mylan, with U.S. headquarters in Canonsburg, Penn.

More Information

Copyright © 2018 HealthDay. All rights reserved.

Physicians Weekly

Recent Posts

  • Reuters

Teleflex recalls breathing tubes worldwide after reports of 4 deaths

(Reuters) - Teleflex Inc said on Monday it plans to recall some lots of its Hudson RCI Sheridan endotracheal tubes…

17 mins ago
  • Reuters

Music playlists could help dementia patients

By Carolyn Crist Personalized music playlists that rekindle memories of childhood and happy moments may bring joy to dementia patients,…

34 mins ago
  • Reuters

Conatus Pharma to explore options as liver disease drug fails trial

(Reuters) - Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its…

43 mins ago
  • Reuters

Oklahoma judge approves Teva’s $85 million opioid settlement

By Nate Raymond (Reuters) - An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries…

1 hour ago
  • Reuters

Young women smokers at much higher risk of deadly heart attack

By Linda Carroll While smoking boosts the likelihood of heart attack in both men and women of all ages, it…

1 hour ago
  • Reuters

Supreme Court to hear insurers’ bid for $12 billion in Obamacare money

By Nate Raymond (Reuters) - The U.S. Supreme Court on Monday agreed to decide whether insurers can seek $12 billion…

2 hours ago
avtomaticheskij-poliv.com.ua

красивые детские платья

www.niko-centre.kiev.ua